Pfizer Inc. $PFE Shares Sold by Burney Co.

Burney Co. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 51.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,917 shares of the biopharmaceutical company’s stock after selling 81,073 shares during the quarter. Burney Co.’s holdings in Pfizer were worth $1,840,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Westbourne Investments Inc. bought a new position in shares of Pfizer during the 1st quarter worth about $2,411,000. Bourne Lent Asset Management Inc. increased its position in shares of Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. Strs Ohio bought a new stake in shares of Pfizer during the first quarter valued at approximately $49,968,000. IFM Investors Pty Ltd increased its position in shares of Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after purchasing an additional 41,263 shares during the period. Finally, Intrua Financial LLC increased its position in shares of Pfizer by 17.4% during the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after purchasing an additional 11,643 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $24.32 on Wednesday. The firm has a market cap of $138.24 billion, a PE ratio of 12.93, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $28.00. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $24.75 and its two-hundred day moving average price is $24.33.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PFE. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.24.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.